Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34958499)

  • 1. Recent advances in the diagnosis, classification and molecular pathogenesis of cutaneous mesenchymal neoplasms.
    Papke DJ; Hornick JL
    Histopathology; 2022 Jan; 80(1):216-232. PubMed ID: 34958499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene fusions in superficial mesenchymal neoplasms: Emerging entities and useful diagnostic adjuncts.
    Fischer GM; Papke DJ
    Semin Diagn Pathol; 2023 Jul; 40(4):246-257. PubMed ID: 37156707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrohistiocytic tumors of the skin: a heterogeneous group of superficially located mesenchymal neoplasms].
    Mentzel T
    Pathologe; 2015 Feb; 36(1):79-88. PubMed ID: 25589356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?
    Hornick JL
    Mod Pathol; 2020 Jan; 33(Suppl 1):56-65. PubMed ID: 31653978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
    Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
    Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma.
    Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O
    J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939
    [No Abstract]   [Full Text] [Related]  

  • 7. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
    Wick MR; Ritter JH; Lind AC; Swanson PE
    Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular fibrous histiocytoma of the skin: evidence of a clonal process with different karyotype from dermatofibrosarcoma.
    Vanni R; Marras S; Faa G; Licheri S; Daniele GM; Fletcher CD
    Genes Chromosomes Cancer; 1997 Apr; 18(4):314-7. PubMed ID: 9087573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
    Cohen PR; Rapin RP; Farhood AI
    Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477
    [No Abstract]   [Full Text] [Related]  

  • 10. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma.
    Sandberg AA; Bridge JA
    Cancer Genet Cytogenet; 2003 Jan; 140(1):1-12. PubMed ID: 12550751
    [No Abstract]   [Full Text] [Related]  

  • 11. An update on selected cutaneous (myo) fibroblastic mesenchymal tumors.
    Georgantzoglou N; Linos K
    Semin Diagn Pathol; 2023 Jul; 40(4):295-305. PubMed ID: 37150655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
    Okita H; Ohtsuka T; Yamazaki S
    Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of ERG immunostaining in dermatofibroma.
    Yamada Y; Ichiki T; Susuki Y; Yamada-Nozaki Y; Tateishi Y; Furue M; Oda Y
    J Clin Pathol; 2023 Aug; 76(8):536-540. PubMed ID: 35318257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
    Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
    Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant cell fibroblastoma in a child misdiagnosed as a dermatofibroma.
    Nguyen CM; Burch JM; Fitzpatrick JE; Peterson SL; Weston WL
    Pediatr Dermatol; 2002; 19(1):28-32. PubMed ID: 11860566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcomas--a clinicopathological guide with particular reference to cutaneous manifestation. I. Dermatofibrosarcoma protuberans, malignant fibrous histiocytoma and the epithelioid sarcoma of Enzinger.
    Fletcher CD; McKee PH
    Clin Exp Dermatol; 1984 Sep; 9(5):451-65. PubMed ID: 6091955
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms.
    Costigan DC; Doyle LA
    Histopathology; 2016 May; 68(6):776-95. PubMed ID: 26763770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous and subcutaneous fibrohistiocytic tumors of intermediate malignancy: an update.
    Billings SD; Folpe AL
    Am J Dermatopathol; 2004 Apr; 26(2):141-55. PubMed ID: 15024197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
    Abdaljaleel MY; North JP
    Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.
    Doyle LA; Mariño-Enriquez A; Fletcher CD; Hornick JL
    Mod Pathol; 2015 Jul; 28(7):904-12. PubMed ID: 25857825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.